Shrna-based targeting of makap?? In heart failure

Ended Project Grant Awarded Last action

Award ID
R44HL147631
Recipient
Awarding agency
Obligated
$7,388,461

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Funding
  • $5,626,477.00 Federal
  • $1,761,984.00 Non-federal
Place of performance
Los Altos, CA 94024, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $885,032 $0
Amendment $885,032 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,761,984 $0
Amendment $1,761,984 $1,761,984
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment Shrna-based targeting of makap?? In heart failure - pathological cardiac remodeling constitutes a common pathway to heart failure in disease. Despite current… $0 $0
Amendment $0 $0
Original award $332,445 $0
Show all 22

Quick answers

Who received award R44HL147631?

R44HL147631 was awarded to CRI Biotech, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on July 1, 2019.

How much is award R44HL147631 worth?

$7,388,461 has been obligated on R44HL147631: $5,626,477 in federal funding and $1,761,984 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award